Tresiba Side-Effect Reports from Real Users

Where These Reports Come From and Why Selection Bias Matters

Patient-reported side-effect data from online communities reflects a self-selected population. People with strong reactions, positive or negative, post more often than those with uneventful experiences. That distortion is real and worth naming upfront.

The reports synthesized here draw from Reddit communities (r/diabetes, r/diabetes_t1, r/diabetes_t2), Drugs.com user reviews (approximately 200 ratings as of early 2026), and threads on diabetes-specific forums like TuDiabetes. No single online platform constitutes a controlled study. Sample sizes are small, demographics skew younger and more tech-literate than the general insulin-using population, and dosing details are often incomplete. A 2020 systematic review in the Journal of Medical Internet Research found that patient forum reports correlate moderately with pharmacovigilance signals but tend to over-represent acute, visible side effects like injection-site reactions while under-reporting metabolic changes like modest A1C drift (source). Every patient anecdote below should be read through that lens.

The DEVOTE trial (N=7,637), published in the New England Journal of Medicine in 2017, remains the largest randomized cardiovascular outcomes study for insulin degludec and provides the clinical anchor against which these patient reports are measured (1).

Injection-Site Reactions: The Most Visible Complaint

Bruising, small hard lumps, and occasional stinging at the injection site dominate the negative-experience threads. On Drugs.com, roughly 15% of reviewers who gave Tresiba a score below 6 mentioned injection-site problems specifically.

Reddit user accounts describe pea-sized nodules that persist for days, particularly when injecting into the abdomen without adequate site rotation. One frequently cited pattern: users who switched from Lantus (glargine U100) report that Tresiba's injection itself stings less, but that the subcutaneous depot sometimes leaves a firmer lump. The FDA prescribing information for Tresiba lists lipodystrophy and injection-site reactions among labeled adverse events, with lipodystrophy reported in 0.6% of trial participants (2).

A practical note from endocrinology guidelines: the American Diabetes Association's Standards of Care recommend rotating injection sites across quadrants of the abdomen, thighs, and upper arms, and avoiding repeated injection into the same 2 cm area for at least 4 weeks to reduce lipohypertrophy risk (3).

Short sentence for emphasis: Site rotation prevents most of these issues.

Nocturnal Hypoglycemia: Where Tresiba Outperforms Expectations

The single most praised attribute of Tresiba across every patient platform is fewer overnight lows. This aligns directly with DEVOTE data. In that trial, insulin degludec reduced the rate of severe nocturnal hypoglycemia by 40% compared to insulin glargine U100 (rate ratio 0.60 to 95% CI 0.44 to 0.82, P=0.001) (1).

Reddit users in r/diabetes_t1 describe the shift vividly. Posts describe going from waking up 3 to 4 nights per week with blood glucose below 60 mg/dL on Lantus, to rarely triggering a continuous glucose monitor low alarm on Tresiba. One user with type 1 diabetes wrote: "Switched after 8 years on Lantus. First week I slept through the night without a single CGM alarm. That hadn't happened in years."

Drugs.com reviews echo this pattern. Among the approximately 200 reviews, users rating Tresiba 8 or above overwhelmingly cite "no more nighttime lows" or "finally sleeping through the night" as the primary reason for the high score. The pharmacokinetic explanation is straightforward: degludec's 25-hour half-life produces a flatter action profile than glargine U100's 12-hour peak, distributing glucose-lowering effect more evenly across 24 hours (4).

The clinical bottom line from the Endocrine Society: for patients experiencing recurrent nocturnal hypoglycemia on first-generation basal insulins, switching to degludec or glargine U300 is a supported clinical strategy (5).

Weight Gain: The Quiet Frustration

Weight gain on basal insulin is expected. Patients know this intellectually, but the emotional impact surfaces repeatedly in forum posts. Tresiba users report gaining 2 to 5 kg (roughly 4 to 11 pounds) during the first 6 to 12 months, consistent with the BEGIN and DEVOTE trial data where degludec-treated patients gained a mean of 2.0 kg over 2 years versus 1.6 kg for glargine (1).

The difference between the two arms was not statistically significant, which means Tresiba does not cause meaningfully more weight gain than its comparator. But patients on Reddit do not compare themselves to a glargine control arm. They compare themselves to their pre-insulin body weight, and the gain feels substantial. Posts in r/diabetes_t2 frequently pair weight frustration with questions about adding a GLP-1 receptor agonist. This reflects the growing clinical trend toward combining basal insulin with semaglutide or tirzepatide to offset insulin-associated weight gain, a strategy endorsed by the American Diabetes Association's 2024 consensus report on type 2 diabetes pharmacotherapy (3).

One pattern worth noting: users who report the largest weight gains (5+ kg) also tend to describe undertreated postprandial glucose, suggesting that some of the gain may stem from overall glycemic management gaps rather than the basal insulin itself.

Morning Hyperglycemia During Titration

A recurring complaint, especially in the first 3 to 4 weeks, is fasting blood glucose that remains stubbornly above target. Users describe starting Tresiba at 10 units, titrating by 2 units every 3 days per their endocrinologist's guidance, and still seeing fasting readings of 140 to 180 mg/dL for weeks.

This frustration has a pharmacokinetic explanation. Degludec takes 3 to 4 days to reach steady state after each dose adjustment because of its ultra-long half-life. Patients accustomed to Lantus, where dose changes take effect within 24 to 48 hours, perceive Tresiba as "not working" during this lag. The prescribing information specifies that dose adjustments should be made no more frequently than every 3 to 4 days, and that steady state is typically reached after 3 to 4 dose adjustments (2).

Reddit threads that track this trajectory show a consistent arc: initial disappointment at weeks 1 to 2, followed by stabilization by weeks 3 to 5, followed by enthusiastic posts about flat CGM tracings. The slow onset is a feature of the molecule's design, not a flaw, but clinicians may need to set this expectation explicitly at the point of prescribing.

Dosing Flexibility: Universally Appreciated

Tresiba's 8-hour dosing window (the ability to shift injection time by up to 8 hours from the usual time without loss of glycemic control) is cited as a significant quality-of-life improvement in nearly every positive review. Shift workers, frequent travelers, and parents of young children with type 1 diabetes mention this feature specifically.

The BEGIN Flex trial (N=687) demonstrated that a forced flexible dosing schedule, with intervals alternating between 8 and 40 hours, achieved non-inferior A1C reduction compared to same-time-daily dosing, with no increase in hypoglycemia (6). Real-world forum reports confirm this: users describe forgetting a dose by 4 to 6 hours, injecting late, and seeing no spike on their CGM.

This flexibility is not shared by all basal insulins. Glargine U100 and U300 both recommend fixed once-daily timing. For patients with irregular schedules, this pharmacologic property alone drives preference.

Cost: The Dominant Negative Theme

Approximately 40% of Drugs.com reviews that give Tresiba a rating of 5 or below cite cost rather than a clinical side effect. Without insurance, Tresiba's list price has historically exceeded $400 per pen package. Even with commercial insurance, copays of $50 to $150 per month appear in patient posts.

Novo Nordisk offers a savings card that can reduce costs for commercially insured patients, and biosimilar competition in the basal insulin space is expanding. The FDA approved insulin degludec-ykgn (the first degludec biosimilar candidate in the pipeline) pathway discussions in 2025, which may reduce prices in coming years (7).

For patients on Medicare Part D, the Inflation Reduction Act's $35 monthly insulin cap applies to Tresiba, a policy change that multiple Reddit users in r/diabetes have described as "life-changing" since its implementation.

Comparison to Lantus and Toujeo in Patient Perception

Head-to-head user comparisons between Tresiba, Lantus (glargine U100), and Toujeo (glargine U300) appear frequently in diabetes forums. The consistent pattern across hundreds of posts:

Tresiba versus Lantus: patients switching to Tresiba report fewer nocturnal lows, less injection-site burning, and greater dosing flexibility. The trade-off most commonly mentioned is cost, as Lantus biosimilars (Semglee, Rezvoglar) are substantially cheaper.

Tresiba versus Toujeo: the distinction is less dramatic. Both are ultra-long-acting, both show flat action profiles, and both reduce nocturnal hypoglycemia compared to glargine U100. A 2019 meta-analysis in Diabetes, Obesity and Metabolism found no significant difference in A1C reduction or hypoglycemia rates between degludec and glargine U300 across 4 randomized trials (8). Patient forums reflect this: users who have tried both describe them as "basically interchangeable," with preference often determined by insurance formulary placement rather than clinical experience.

The DEVOTE trial's primary finding, non-inferiority to glargine U100 on major adverse cardiovascular events (MACE), provides the safety foundation that lets clinicians recommend Tresiba for patients with established cardiovascular disease. The hazard ratio for MACE was 0.91 (95% CI 0.78 to 1.06), with no cardiovascular safety signal (1).

Pediatric and Type 1-Specific Reports

Parents of children with type 1 diabetes form a distinct and vocal subgroup on Reddit (r/diabetes_t1, r/parents). Their reports highlight two Tresiba-specific advantages: the U200 concentration allows half the injection volume for children on higher doses, reducing injection pain, and the dosing flexibility accommodates unpredictable school and activity schedules.

The most commonly reported side effect in pediatric threads is injection-site bruising, consistent with adult reports. A 2018 randomized trial in pediatric type 1 diabetes (N=350) demonstrated non-inferior A1C control with degludec versus detemir, with a 0.16 percentage-point lower A1C in the degludec group and no safety signals (9).

Negative pediatric reports center on the same titration-lag frustration described above, compounded by the difficulty of explaining pharmacokinetic steady-state concepts to a worried parent watching their child's fasting glucose stay elevated for 2 weeks after starting a new insulin.

Rare but Reported: Allergic Reactions and Headaches

A small number of Drugs.com reviews (fewer than 5% of total) describe generalized itching, rash, or headache after starting Tresiba. These reports are difficult to attribute specifically to degludec versus the metacresol preservative common to most insulin formulations. The FDA label lists hypersensitivity reactions as a warning, with anaphylaxis reported in post-marketing surveillance at a rate too low to quantify (2).

Headaches reported in the first week of therapy may also reflect rapid glucose changes during initial titration rather than a direct drug effect. No controlled trial has identified headache as a statistically significant adverse event for degludec compared to active comparators.

Putting the Reports in Clinical Context

Real-world patient reports on Tresiba cluster around a consistent profile: injection-site reactions and weight gain as the primary complaints, with dosing flexibility and fewer nocturnal lows as the primary benefits. Cost remains the single largest barrier to satisfaction. The DEVOTE trial's cardiovascular safety data and the 40% reduction in severe nocturnal hypoglycemia (rate ratio 0.60, P=0.001) provide the evidence base that supports what patients describe anecdotally. For patients currently experiencing recurrent overnight lows on glargine U100 or who need schedule flexibility, a trial of degludec at a starting dose of 10 units once daily (type 2) or one-third of total daily basal dose (type 1), titrated by 2 units every 3 to 4 days to a fasting glucose target of 80 to 130 mg/dL, aligns with both ADA Standards of Care and the lived experience documented across thousands of patient posts (3).